Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 3620510, 14 pages
https://doi.org/10.1155/2017/3620510
Research Article

Recombinant Vaccinia Viruses Coding Transgenes of Apoptosis-Inducing Proteins Enhance Apoptosis But Not Immunogenicity of Infected Tumor Cells

1Department of Biotechnology, Institute of Chemical Biology and Fundamental Medicine, SB RAS, Novosibirsk, Russia
2Department of Natural Sciences, Novosibirsk State University, Novosibirsk, Russia
3Department of Viral Hepatitis, State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, Koltsovo, Russia

Correspondence should be addressed to Olga Koval; ur.sgn@lavok_o

Received 25 April 2017; Revised 17 July 2017; Accepted 26 July 2017; Published 30 August 2017

Academic Editor: Steven De Vleeschouwer

Copyright © 2017 Olga Koval et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Fukuhara, Y. Ino, and T. Todo, “Oncolytic virus therapy: A new era of cancer treatment at dawn,” Cancer Science, vol. 107, no. 10, pp. 1373–1379, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. L. Fang, Q. Cheng, W. Li et al., “Antitumor activities of an oncolytic adenovirus equipped with a double siRNA targeting Ki67 and hTERT in renal cancer cells,” Virus Research, vol. 181, pp. 61–71, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. Z. S. Guo, Z. Liu, and D. L. Bartlett, “Oncolytic immunotherapy: Dying the right way is a key to eliciting potent antitumor immunity,” Frontiers in Oncology, vol. 4, Article ID 74, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Rodriguez-Rocha, J. G. Gomez-Gutierrez, A. Garcia-Garcia et al., “Adenoviruses induce autophagy to promote virus replication and oncolysis,” Virology, vol. 416, no. 1-2, pp. 9–15, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Liskova, J. Knitlova, R. Honner, and Z. Melkova, “Apoptosis and necrosis in vaccinia virus-infected HeLa G and BSC-40 cells,” Virus Research, vol. 160, no. 1-2, pp. 40–50, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. L. M. Whilding, K. M. Archibald, H. Kulbe, F. R. Balkwill, D. Öberg, and I. A. McNeish, “Vaccinia Virus induces programmed necrosis in ovarian cancer cells,” Molecular Therapy, vol. 21, no. 11, pp. 2074–2086, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. M. J. Wilkinson, H. G. Smith, G. McEntee et al., “Oncolytic vaccinia virus combined with radiotherapy induces apoptotic cell death in sarcoma cells by down-regulating the inhibitors of apoptosis,” Oncotarget, vol. 7, no. 49, pp. 81208–81222, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. J. L. Connolly, E. S. Barton, and T. S. Dermody, “Reovirus binding to cell surface sialic acid potentiates virus-induced apoptosis,” Journal of Virology, vol. 75, no. 9, pp. 4029–4039, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. B. E. Hiller, A. K. Berger, and P. Danthi, “Viral gene expression potentiates reovirus-induced necrosis,” Virology, vol. 484, pp. 386–394, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Pol, A. Buqué, F. Aranda et al., “Trial Watch—Oncolytic viruses and cancer therapy,” OncoImmunology, vol. 5, no. 2, Article ID e1117740, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. G. L. Smith, C. T. O. Benfield, C. Maluquer de Motes et al., “Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity,” Journal of General Virology, vol. 94, no. 11, pp. 2367–2392, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Strnadova, H. Ren, R. Valentine et al., “Inhibition of Translation Initiation by Protein 169: A Vaccinia Virus Strategy to Suppress Innate and Adaptive Immunity and Alter Virus Virulence,” PLoS Pathogens, vol. 11, no. 9, Article ID e1005151, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. C. J. Breitbach, K. Parato, J. Burke, T.-H. Hwang, J. C. Bell, and D. H. Kirn, “Pexa-Vec double agent engineered vaccinia: Oncolytic and active immunotherapeutic,” Current Opinion in Virology, vol. 13, pp. 49–54, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. Z. Liu, R. Ravindranathan, J. Li, P. Kalinski, Z. S. Guo, and D. L. Bartlett, “CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy,” OncoImmunology, vol. 5, no. 3, Article ID e1091554, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Parviainen, M. Ahonen, I. Diaconu et al., “CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging,” Gene Therapy, vol. 21, no. 2, pp. 195–204, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. C. J. Breitbach, S. H. Thorne, J. C. Bell, and D. H. Kirn, “Targeted and armed oncolytic poxviruses for cancer: The lead example of JX-594,” Current Pharmaceutical Biotechnology, vol. 13, no. 9, pp. 1768–1772, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. N. Casares, M. O. Pequignot, A. Tesniere et al., “Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death,” The Journal of Experimental Medicine, vol. 202, no. 12, pp. 1691–1701, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Ma, S. Adjemian, S. R. Mattarollo et al., “Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells,” Immunity, vol. 38, no. 4, pp. 729–741, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. D. V. Krysko, A. D. Garg, A. Kaczmarek, O. Krysko, P. Agostinis, and P. Vandenabeele, “Immunogenic cell death and DAMPs in cancer therapy,” Nature Reviews Cancer, vol. 12, no. 12, pp. 860–875, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. I. Diaconu, V. Cerullo, M. L. M. Hirvinen et al., “Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus,” Cancer Research, vol. 72, no. 9, pp. 2327–2338, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. S. T. Workenhe, G. Simmons, J. G. Pol, B. D. Lichty, W. P. Halford, and K. L. Mossman, “Immunogenic HSV-mediated Oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy,” Molecular Therapy, vol. 22, no. 1, pp. 123–131, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. S. T. Workenhe and K. L. Mossman, “Oncolytic virotherapy and immunogenic cancer cell death: Sharpening the sword for improved cancer treatment strategies,” Molecular Therapy, vol. 22, no. 2, pp. 251–256, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. T. L. Aaes, A. Kaczmarek, T. Delvaeye et al., “Vaccination with Necroptotic Cancer Cells Induces Efficient Anti-tumor Immunity,” Cell Reports, vol. 15, no. 2, pp. 274–287, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Kochneva, G. Sivolobova, A. Tkacheva et al., “Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy,” Oncotarget, vol. 7, no. 45, pp. 74171–74188, 2016. View at Publisher · View at Google Scholar · View at Scopus
  25. G. V. Kochneva, I. N. Babkina, T. A. Lupan et al., “Apoptin enhances the oncolytic activity of vaccinia virus in vitro,” Molecular Biology, vol. 47, no. 5, pp. 733–742, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Los, S. Panigrahi, I. Rashedi et al., “Apoptin, a tumor-selective killer,” Biochimica et Biophysica Acta - Molecular Cell Research, vol. 1793, no. 8, pp. 1335–1342, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. M. H. M. Noteborn, C. A. J. Verschueren, A. Zantema, G. Koch, and A. J. van der Eb, “Identification of the promoter region of chicken anemia virus (CAV) containing a novel enhancer-like element,” Gene, vol. 150, no. 2, pp. 313–318, 1994. View at Publisher · View at Google Scholar · View at Scopus
  28. A. A. Grazhdantseva, G. F. Sivolobova, A. V. Tkacheva et al., “Highly effective production of biologically active, secreted, human granulocyte-macrophage colony-stimulating factor by recombinant vaccinia virus,” Applied Biochemistry and Microbiology, vol. 52, no. 7, pp. 685–691, 2016. View at Publisher · View at Google Scholar · View at Scopus
  29. G. Kochneva, E. Zonov, A. Grazhdantseva et al., “Apoptin enhances the oncolytic properties of vaccinia virus and modifies mechanisms of tumor regression,” Oncotarget, vol. 5, no. 22, pp. 11269–11282, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Kochneva, I. Kolosova, T. Maksyutova, E. Ryabchikova, and S. Shchelkunov, “Effects of deletions of kelch-like genes on cowpox virus biological properties,” Archives of Virology, vol. 150, no. 9, pp. 1857–1870, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. S. T. Smiley, M. Reers, C. Mottola-Hartshorn et al., “Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1,” Proceedings of the National Academy of Sciences, vol. 88, no. 9, pp. 3671–3675, 1991. View at Publisher · View at Google Scholar
  32. O. Kepp, L. Senovilla, I. Vitale, E. Vacchelli, S. Adjemian, P. Agostinis et al., “Consensus guidelines for the detection of immunogenic cell death,” OncoImmunology, vol. 3, no. 9, Article ID e955691, 2014. View at Publisher · View at Google Scholar
  33. T.-J. Lin, H.-T. Lin, W.-T. Chang et al., “Shikonin-enhanced cell immunogenicity of tumor vaccine is mediated by the differential effects of DAMP components,” Molecular Cancer, vol. 14, no. 1, article no. 174, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. R. Spisek, A. Charalambous, A. Mazumder, D. H. Vesole, S. Jagannath, and M. V. Dhodapkar, “Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: Therapeutic implications,” Blood, vol. 109, no. 11, pp. 4839–4845, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Hofmann, S. Weibel, and A. A. Szalay, “Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice,” Journal of Translational Medicine, vol. 12, no. 1, article no. 197, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Siurala, S. Bramante, L. Vassilev et al., “Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma,” International Journal of Cancer, vol. 136, no. 4, pp. 945–954, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Pandha, G. Simpson, K. Relph, A. Melcher, and K. Harrington, “Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances,” Oncolytic Virotherapy, vol. 5, pp. 1–13, 2016. View at Publisher · View at Google Scholar
  38. M. J. Wilkinson, H. G. Smith, T. D. Pencavel et al., “Isolated limb perfusion with biochemotherapy and oncolytic virotherapy combines with radiotherapy and surgery to overcome treatment resistance in an animal model of extremity soft tissue sarcoma,” International Journal of Cancer, vol. 139, no. 6, pp. 1414–1422, 2016. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Wang, N. G. Chen, B. R. Minev, and A. A. Szalay, “Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells,” Journal of Translational Medicine, vol. 10, no. 1, article no. 167, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. S. T. Wasilenko, L. Banadyga, D. Bond, and M. Barry, “The vaccinia virus F1L protein interacts with the proapoptotic protein Bak and inhibits Bak activation,” Journal of Virology, vol. 79, no. 22, pp. 14031–14043, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. G. J. Kotwal and B. Moss, “Vaccinia virus encodes two proteins that are structurally related to members of the plasma serine protease inhibitor superfamily,” Journal of Virology, vol. 63, no. 2, pp. 600–606, 1989. View at Google Scholar · View at Scopus
  42. O. A. Koval, A. V. Tkachenko, A. S. Fomin et al., “Lactaptin induces p53-independent cell death associated with features of apoptosis and autophagy and delays growth of breast cancer cells in mouse xenografts,” PLoS ONE, vol. 9, no. 4, Article ID e93921, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. Y. N. Lezhnin, Y. E. Kravchenko, E. I. Frolova, P. M. Chumakov, and S. P. Chumakov, “Oncotoxic proteins in cancer therapy: Mechanisms of action,” Molecular Biology, vol. 49, no. 2, Article ID 26065254, pp. 231–243, 2015. View at Publisher · View at Google Scholar
  44. E. Yu, D. Zhai, C. Jin, M. Gerlic, J. C. Reed, and R. Liddington, “Structural determinants of caspase-9 inhibition by the vaccinia virus protein, F1L,” Journal of Biological Chemistry, vol. 286, no. 35, pp. 30748–30758, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Campbell, J. Thibault, N. Mehta, P. M. Colman, M. Barry, and M. Kvansakul, “Structural insight into BH3 domain binding of vaccinia virus antiapoptotic F1L,” Journal of Virology, vol. 88, no. 15, pp. 8667–8677, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. O. A. Koval, A. S. Fomin, V. I. Kaledin et al., “A novel pro-apoptotic effector lactaptin inhibits tumor growth in mice models,” Biochimie, vol. 94, no. 12, pp. 2467–2474, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Burek, S. Maddika, C. J. Burek, P. T. Daniel, K. Schulze-Osthoff, and M. Los, “Apoptin-induced cell death is modulated by Bcl-2 family members and is Apaf-1 dependent,” Oncogene, vol. 25, no. 15, pp. 2213–2222, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. P. S. Frisa and J. W. Jacobberger, “Cell cycle-related cyclin B1 quantification,” PLoS ONE, vol. 4, no. 9, Article ID e7064, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. H. J. Choi, M. Fukui, and B. T. Zhu, “Role of cyclin B1/Cdc2 up-regulation in the development of mitotic prometaphase arrest in human breast cancer cells treated with nocodazole,” PLoS ONE, vol. 6, no. 8, Article ID e24312, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Dougan and G. Dranoff, “Immune therapy for cancer,” Annual Review of Immunology, vol. 27, no. 1, pp. 83–117, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Vanneman and G. Dranoff, “Combining immunotherapy and targeted therapies in cancer treatment,” Nature Reviews Cancer, vol. 12, no. 4, pp. 237–251, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Tesniere, F. Schlemmer, V. Boige et al., “Immunogenic death of colon cancer cells treated with oxaliplatin,” Oncogene, vol. 29, no. 4, pp. 482–491, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. C. A. Koks, A. D. Garg, M. Ehrhardt et al., “Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death,” International Journal of Cancer, vol. 136, no. 5, pp. E313–E325, 2015. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Miyamoto, H. Inoue, T. Nakamura et al., “Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma,” Cancer Research, vol. 72, no. 10, pp. 2609–2621, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Hemminki, M. Wang, T. Hakkarainen, R. A. Desmond, J. Wahlfors, and D. T. Curiel, “Production of an EGFR targeting molecule from a conditionally replicating adenovirus impairs its oncolytic potential,” Cancer Gene Therapy, vol. 10, no. 8, pp. 583–588, 2003. View at Publisher · View at Google Scholar · View at Scopus
  56. R. P. Sumner, H. Ren, B. J. Ferguson, and G. L. Smith, “Increased attenuation but decreased immunogenicity by deletion of multiple vaccinia virus immunomodulators,” Vaccine, vol. 34, no. 40, pp. 4827–4834, 2016. View at Publisher · View at Google Scholar · View at Scopus
  57. Y. Luo, Y. Chihara, K. Fujimoto et al., “High mobility group box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy,” European Journal of Cancer, vol. 49, no. 3, pp. 741–751, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. J. Wang, Q. Li, Y. Ou et al., “Inhibition of tumor growth by recombinant adenovirus containing human lactoferrin through inducing tumor cell apoptosis in mice bearing EMT6 breast cancer,” Archives of Pharmacal Research, vol. 34, no. 6, pp. 987–995, 2011. View at Publisher · View at Google Scholar · View at Scopus